FBXW18 Activators
Fbxw18, encoding the F-box and WD-40 domain protein 18, is a gene with significant implications for cellular homeostasis, particularly in the context of protein degradation and signal transduction. As an integral component of the SCF E3 ligase complex, Fbxw18 plays a crucial role in ubiquitin-mediated protein degradation. Its F-box domain facilitates substrate recognition, targeting specific proteins for ubiquitination and subsequent degradation by the proteasome. The WD-40 domain, known for its versatility in protein-protein interactions, likely contributes to the intricate regulatory network that governs Fbxw18's activity. Activation of Fbxw18 is intricately linked to the modulation of various signaling pathways, emphasizing its multifaceted role in cellular processes. While direct activators for Fbxw18 remain elusive, several chemicals have been identified that potentially influence Fbxw18 indirectly. These include inhibitors of CK2, proteasome, NEDD8-activating enzyme, and various components of signaling pathways such as MAPK, PI3K/AKT, JNK, mTOR, and STAT3.
The interplay between these chemicals and cellular processes highlights the complexity of Fbxw18 regulation. For instance, inhibiting CK2 disrupts phosphorylation events crucial for Fbxw18 function, while proteasome inhibitors prevent Fbxw18 degradation, potentially leading to increased Fbxw18 activity. Additionally, modulation of signaling pathways by specific inhibitors may indirectly affect Fbxw18 activation by altering the cellular environment and signaling cascades associated with Fbxw18's functions. In conclusion, Fbxw18 emerges as a pivotal player in cellular homeostasis, particularly in the realm of protein degradation and signal transduction. Its activation is tightly regulated, involving intricate interactions with various cellular components and signaling pathways. While direct activators for Fbxw18 are yet to be identified, the indirect modulation of its activity through specific chemicals underscores the need for further exploration into the precise mechanisms governing Fbxw18 in the intricate landscape of cellular regulation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
CX-4945 | 1009820-21-6 | sc-364475 sc-364475A | 2 mg 50 mg | $183.00 $800.00 | 9 | |
CK2 inhibitor impacting cellular processes. CK2 phosphorylates Fbxw18, modulating its function. Inhibition of CK2 disrupts this regulatory mechanism, potentially leading to increased Fbxw18 activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Proteasome inhibitor affecting protein degradation. Fbxw18 is degraded through the ubiquitin-proteasome system. Bortezomib prevents Fbxw18 degradation, potentially leading to increased Fbxw18 activity. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $280.00 | 1 | |
NEDD8-activating enzyme (NAE) inhibitor. Fbxw18 is part of the SCF E3 ligase complex, and NAE activity is essential for SCF complex function. Inhibition of NAE by MLN4924 may influence Fbxw18 stability and activation. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Raf kinase inhibitor impacting MAPK pathway. Fbxw18 interacts with components of the MAPK pathway. Sorafenib's action on MAPK signaling may indirectly affect Fbxw18 activity by influencing the upstream pathway components. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor modulating cellular processes. Fbxw18 is associated with mTOR signaling. Rapamycin's inhibition of mTOR may indirectly impact Fbxw18 activation by altering the cellular environment and signaling cascades related to Fbxw18 function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
MEK inhibitor affecting MAPK pathway. Fbxw18 interacts with components of the MAPK pathway. PD98059's action on MAPK signaling may indirectly influence Fbxw18 activity by modulating the upstream components of the pathway and affecting the signaling cascade involving Fbxw18. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor impacting cellular processes. Fbxw18 is linked to the JNK signaling pathway. SP600125's action on JNK may indirectly affect Fbxw18 activation by modulating the signaling cascade and influencing downstream targets that interact with Fbxw18. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
Immunomodulatory drug. Fbxw18 is involved in immune response pathways. Thalidomide's immunomodulatory effects may indirectly impact Fbxw18 activity by influencing the cellular environment and signaling cascades associated with Fbxw18's immune-related functions. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
MEK inhibitor affecting MAPK pathway. Fbxw18 interacts with components of the MAPK pathway. Trametinib's action on MAPK signaling may indirectly influence Fbxw18 activity by modulating the upstream components of the pathway and affecting the signaling cascade involving Fbxw18. | ||||||
Niclosamide | 50-65-7 | sc-250564 sc-250564A sc-250564B sc-250564C sc-250564D sc-250564E | 100 mg 1 g 10 g 100 g 1 kg 5 kg | $37.00 $77.00 $184.00 $510.00 $1224.00 $5814.00 | 8 | |
STAT3 inhibitor impacting intracellular signaling. Fbxw18 is associated with STAT3 signaling. Niclosamide's inhibition of STAT3 may indirectly activate Fbxw18 by altering the cellular environment and signaling cascades related to Fbxw18 function. | ||||||